Advanced search
Publication Cover
Neurobehavioral HIV Medicine Volume 7, 2016 - Issue
Journal homepage
123
Views
2
CrossRef citations to date
0
Altmetric
Review

Chronic distress and the vulnerable host: a new target for HIV treatment and prevention?

Carlo Contoreggi1 Intramural Research Program (IRP), National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH), Baltimore, MD, USA
,
George P Chrousos2 Department of Pediatrics, Aghia Sophia Children’s Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece
&
Michele Di Mascio3 AIDS Imaging Research Section, Division of Clinical Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USACorrespondence[email protected]
Pages 53-75 | Published online: 28 Dec 2016

References

  • Centers for Disease Control and Prevention. HIV Among Gay and Bisexual Men. [webpage on the Internet]. Available from: http://www.cdc.gov/hiv/group/msm/index.html Accessed Nov 11, 2016.
  • Available from: http://www.cdc.gov/nchhstp/newsroom/docs/2012/HIV-Infections-2007–2010.pdf. Accessed Nov 11, 2016.
  • Who is at risk for HIV Infection and Which Populations are Most Affected? [webpage on the Internet]. National Institute on Drug Abuse [updated July 2012]. Available from: http://www.drugabuse.gov/publications/hivaids/who-risk-hiv-infection-which-populations-are-most-affected. Accessed Nov 11, 2015.
  • Persson A, Ellard J, Newman C, Holt M, de Wit J. Human rights and universal access for men who have sex with men and people who inject drugs: a qualitative analysis of the 2010 UNGASS narrative country progress reports. Soc Sci Med. 2011;73(3):467–474.
  • Silverman MN, Sternberg EM. Glucocorticoid regulation of inflammation and its functional correlates: from HPA axis to glucocorticoid receptor dysfunction. Ann N Y Acad Sci. 2012;1261:55–63.
  • Chrousos GP. Stress and disorders of the stress system. Nat Rev Endocrinol. 2009;5(7):374–381.
  • Chrousos GP. Stressors, stress, and neuroendocrine integration of the adaptive response. The 1997 Hans Selye Memorial Lecture. Ann N Y Acad Sci. 1998;851:311–335.
  • Norbiato G, Bevilacqua M, Vago T, Taddei A, Clerici. Glucocorticoids and the immune function in the human immunodeficiency virus infection: a study in hypercortisolemic and cortisol-resistant patients. J Clin Endocrinol Metab. 1997;82:3260–3263.
  • Wang J, Harada A, Matsushita S, et al. IL-4 and a glucocorticoid up-regulate CXCR4 expression on human CD4+ T lymphocytes and enhance HIV-1 replication. J Leukoc Biol. 1998;64(5):642–649.
  • Nair MPN, Mahajan S, Hou J, Sweet AM, Schwartz SA. The stress hormone, cortisol, synergizes with HIV-1 gp-120 to induce apoptosis of normal human peripheral blood mononuclear cells. Cell Mol Biol (Noisy-le-grand). 2000;46(7):1227–1238.
  • Nair MP, Schwartz SA. Synergistic effect of cortisol and HIV-1 envelope peptide on the NK activities of normal lymphocytes. Brain Behav Immun. 1995;9(1):20–30
  • Wiegers K, Schwarck D, Reimer R, Bohn W. Activation of the glucocorticoid receptor releases unstimulated PBMCs from an early block in HIV-1 replication. Virology. 2008;375(1):73–84.
  • “[No authors listed]. Glucocorticoids and mood: clinical manifestations, risk factors and molecular mechanisms. Proceedings of a meeting. June 20–21, 2008. La Jolla, California, USA. Ann N Y Acad Sci. 2009 Oct;1179:vii–viii, 1–233.
  • Chrousos GP, Kino T. Glucocorticoid action networks and complex psychiatric and/or somatic disorders. Stress. 2007;10(2):213–219.
  • Biglino A, Limone P, Forno B, et al. Altered adrenocorticotropin and cortisol response to corticotropin-releasing hormone in HIV-1 infection. Eur J Endocrinol. 1995;133(2):173–179.
  • Kumar M, Kumar AM, Waldrop D, Antoni MH, Schneiderman N, Eisdorfer C. The HPA axis in HIV-1 infection. J Acquir Immune Defic Syndr. 2002;31(Suppl 2):S89–S93.
  • Chittiprol S, Kumar AM, Satishchandra P, et al. Progressive dysregulation of autonomic and HPA axis functions in HIV-1 clade C infection in South India. Psychoneuroendocrinology. 2008;33(1):30–40.
  • Zapanti E, Terzidis K, Chrousos G. Dysfunction of the hypothalamic-pituitary-adrenal axis in HIV infection and disease. Hormones (Athens). 2008;7(3):205–216.
  • Finlayson TJ, Le B, Smith A, et al; Centers for Disease Control and Prevention (CDC). HIV risk, prevention, and testing behaviors among men who have sex with men – National HIV Behavioral Surveillance System, 21 U.S. cities, United States, 2008. MMWR Surveill Summ. 2011;60(14):1–34.
  • Pappas MK, Halkitis PN. Sexual risk taking and club drug use across three age cohorts of HIV-positive gay and bisexual men in New York City. AIDS Care. 2011;23(11):1410–1416.
  • Ghanem A, Little SJ, Drumright L, Liu L, Morris S, Garfein RS. High-risk behaviors associated with injection drug use among recently HIV-infected men who have sex with men in San Diego, CA. AIDS Behav. 2011;15(7):1561–1569.
  • Barabás E, González R, Nagy K, Várkonyi V, Horváth A. No change in impaired cellular immune response of HIV-negative homosexuals after 15 years of HIV epidemic in Eastern/Central European region. J Investig Allergol Clin Immunol. 2001;11(3):172–175.
  • Palmer CD, Tomassilli J, Sirignano M, et al. Enhanced immune activation linked to endotoxemia in HIV-1 seronegative MSM. AIDS. 2014;28(14):2162–2166.
  • Hazenberg MD, Otto SA, van Benthem BH, et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS. 2003;17(13):1881–1888.
  • van Asten L, Danisman F, Otto SA, et al. Pre-seroconversion immune status predicts the rate of CD4 T cell decline following HIV infection. AIDS. 2004;18:1885–1893.
  • Koning FA, Otto SA, Hazenberg MD, et al. Low-level CD4+ T cell activation is associated with low susceptibility to HIV-1 infection. J Immunol. 2005;175:6117–6122.
  • Sandler NG, Douek DC. Microbial translocation in HIV infection: causes, consequences and treatment opportunities. Nat Rev Microbiol. 2012;10(9):655–666.
  • Jiang W, Lederman MM, Hunt P, et al. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis. 2009;199(8):1177–1185.
  • Douek D. HIV disease progression: immune activation, microbes, and a leaky gut. Top HIV Med. 2007;15(4):114–117.
  • Sutton AJ, House T, Hope VD, Ncube F, Wiessing L, Kretzschmar M. Modelling HIV in the injecting drug user population and the male homosexual population in a developed country context. Epidemics. 2012;4:48–56.
  • Zhang ZQ, Wietgrefe SW, Li Q, et al. Roles of substrate availability and infection of resting and activated CD4+ T cells in transmission and acute simian immunodeficiency virus infection. Proc Natl Acad Sci U S A. 2004;101(15):5640–5645.
  • Muñoz FA, Pollini RA, Zúñiga ML, et al. Condom access: associations with consistent condom use among female sex workers in two northern border cities of Mexico. AIDS Educ Prev. 2010;22(5):455–465.
  • Strathdee SA, Lozada R, Martinez G, et al. Social and structural factors associated with HIV infection among female sex workers who inject drugs in the Mexico-US border region. PLoS One. 2011;6(4):e19048.
  • Surratt HL, Inciardi JA. An effective HIV risk-reduction protocol for drug-using female sex workers. J Prev Interv Community. 2010;38(2):118–131.
  • Koob GF. The role of CRF and CRF-related peptides in the dark side of addiction. Brain Res. 2010;1314:3–14.
  • Shalev U, Erb S, Shaham Y. Role of CRF and other neuropeptides in stress-induced reinstatement of drug seeking. Brain Res. 2010;1314:15–28.
  • Shaham Y, Shalev U, Lu L, De Wit H, Stewart J. The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology (Berl). 2003;168(1–2):3–20.
  • Elenkov IJ. Neurohormonal-cytokine interactions: implications for inflammation, common human diseases and well-being. Neurochem Int. 2008;52(1–2):40–51.
  • Calcagni E, Elenkov I. Stress system activity, innate and T helper cytokines, and susceptibility to immune-related diseases. Ann N Y Acad Sci. 2006;1069:62–76.
  • Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES. The sympathetic nerve--an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev. 2000;52(4):595–638.
  • Grammatopoulos DK, Chrousos GP. Functional characteristics of CRH receptors and potential clinical applications of CRH-receptor antagonists. Trends Endocrinol Metab. 2002;13(10):436–444.
  • Alheid GF, Heimer L. New perspectives in basal forebrain organization of special relevance for neuropsychiatric disorders: the striatopallidal, amygdaloid, and corticopetal components of substantia innominata. Neuroscience. 1988;27(1):1–39.
  • Heimer L, Van Hoesen GW. The limbic lobe and its output channels: implications for emotional functions and adaptive behavior. Neurosci Biobehav Rev. 2006;30(2):126–147.
  • Zheng PY, Feng BS, Oluwole C, et al. Psychological stress induces eosinophils to produce corticotrophin releasing hormone in the intestine. Gut. 2009;58(11):1473–1479.
  • Kohno M, Kawahito Y, Tsubouchi Y, et al. Urocortin inflammatory activity. J Clin Endocrinol Metab. 2001;86(9):4344–4352.
  • Taché Y, Martinez V, Wang L, Million M. CRF1 receptor signaling pathways are involved in stress-related alterations of colonic function and viscerosensitivity: implications for irritable bowel syndrome. Br J Pharmacol. 2004;141(8):1321–1330.
  • Wlk M, Wang CC, Venihaki, M et al. Corticotropin-releasing hormone antagonists possess anti-inflammatory effects in the mouse ileum. Gastroenterology. 2002;123(2):505–515.
  • Kokkotou E, Torres D, Moss AC, et al. Corticotropin-releasing hormone receptor 2- deficient mice have reduced intestinal inflammatory responses. J Immunol. 2006;177(5):3355–3361.
  • O’Kane M, Murphy EP, Kirby B. The role of corticotropin-releasing hormone in immune- mediated cutaneous inflammatory disease. Exp Dermatol. 2006;15(3):143–153.
  • Agelaki S, Tsatsanis C, Gravanis A, Margioris AN. Corticotropin-releasing hormone augments proinflammatory cytokine production from macrophages in vitro and in lipopolysaccharide-induced endotoxin shock in mice. Infect Immun. 2002;70(11):6068–6074.
  • Kim BJ, Kayembe K, Simecka JW, Pulse M, Jones HP. Corticotropin-releasing hormone receptor-1 and 2 activity produces divergent resistance against stress-induced pulmonary Streptococcus pneumoniae infection. J Neuroimmunol. 2011;237(1–2):57–65.
  • Webster EL, Barrientos RM, Contoreggi C, et al. Corticotropin releasing hormone (CRH) antagonist attenuates adjuvant induced arthritis: role of CRH in peripheral inflammation. J Rheumatol. 2002;29(6):1252–1261.
  • Goebel M, Stengel A, Wang L, Reeve J Jr, Taché Y. Lipopolysaccharide increases plasma levels of corticotropin-releasing hormone in rats. Neuroendocrinology. 2011;93(3):165–173.
  • Buckinx R, Adriaensen D, Nassauw LV, Timmermans JP. Corticotrophin-releasing factor, related peptides, and receptors in the normal and inflamed gastrointestinal tract. Front Neurosci. 2011;5:54.
  • Wallon C, Söderholm JD. Corticotropin-releasing hormone and mast cells in the regulation of mucosal barrier function in the human colon. Ann N Y Acad Sci. 2009;1165:206–210.
  • Fukudo S. Role of corticotropin-releasing hormone in irritable bowel syndrome and intestinal inflammation. J Gastroenterol. 2007;42(Suppl 17):48–51.
  • Marchetti G, Bellistrì GM, Borghi E, et al. Microbial translocation is associated with sustained failure in CD4+ T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy. AIDS. 2008;22(15):2035–2038.
  • Vassallo M, Mercié P, Cottalorda J, Ticchioni M, Dellamonica P. The role of lipopolysaccharide as a marker of immune activation in HIV-1 infected patients: a systematic literature review. Virol J. 2012;9:174.
  • Elias AN, Meshkinpour H, Valenta LJ, Grossman MK. Pseudo-Cushing’s syndrome: the role of alcohol. J Clin Gastroenterol. 1982;4(2):137–139.
  • Pace TW, Hu F, Miller AH. Cytokine-effects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression. Brain Behav Immun. 2007;21(1):9–19.
  • Sternberg EM. Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens. Nat Rev Immunol. 2006;6(4):318–328.
  • Wang T, Rumbaugh JA, Nath A. Viruses and the brain: from inflammation to dementia. Clin Sci (Lond). 2006;110(4):393–407.
  • Churchill M, Nath A. Where does HIV hide? A focus on the central nervous system. Curr Opin HIV AIDS. 2013;8(3):165–169.
  • Watkins LR, Maier SF, Goehler LE. Cytokine-to-brain communication: a review & analysis of alternative mechanisms. Life Sci. 1995;57:1011–1026.
  • Dantzer R, Aubert A, Bluthé RM, et al. Mechanisms of the behavioural effects of cytokines. In: Dantzer R, Wollman EE, Yirmiya R, editors. Cytokines, Stress, and Depression. New York: Kluwer Academic/Plenum Publishers; 1999:83–105.
  • Banks WA, Farr SA, Morley JE. Entry of blood-borne cytokines into the central nervous system: effects on cognitive processes. Neuroimmunomodulation. 2002–2003;10(6):319–327.
  • Banks WA, Kastin AJ, Broadwell RD. Passage of cytokines across the blood–brain barrier. Neuroimmunomodulation. 1995;2(4):241–248.
  • Tsigos C, Chrousos GP. Hypothalamic-pituitary adrenal axis, neuroendocrine factors and stress. J Psychosom Res. 2002;53:865–871.
  • Raber J, Sorg O, Horn TF, et al. Inflammatory cytokines: putative regulators of neuronal and neuro-endocrine function. Brain Res Brain Res Rev. 1998;26(2–3):320–326.
  • Kronfol Z, Remick DG. Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry. 2000;157(5):683–694.
  • Marques AH, Cizza G, Sternberg E. Interações imunocerebrais e implicações nos transtornos psiquiátricos. [Brain-immune interactions and implications in psychiatric disorders]. Rev Bras Psiquiatr. 2007;29(Suppl 1):S27–S32. Portuguese.
  • Theoharides TC, Rozniecki JJ, Sahagian G, et al. Impact of stress and mast cells on brain metastases. J Neuroimmunol. 2008;205(1–2):1–7.
  • Theoharides TC, Konstantinidou AD. Corticotropin-releasing hormone and the blood- brain-barrier. Front Biosci. 2007;12:1615–1628.
  • Esposito P, Gheorghe D, Kandere K, et al. Acute stress increases permeability of the blood-brain-barrier through activation of brain mast cells. Brain Res. 2001;888(1):117–127.
  • Benou C, Wang Y, Imitola J, et al. Corticotropin-releasing hormone contributes to the peripheral inflammatory response in experimental autoimmune encephalomyelitis. J Immunol. 2005;174(9):5407–5413.
  • Heaton RK, Franklin DR, Ellis RJ, et al; CHARTER Group; HNRC Group. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol. 2011;17(1):3–16.
  • Sacktor N, Lyles RH, Skolasky R, et al; Multicenter AIDS Cohort Study. HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990–1998. Neurology. 2001;56(2):257–260.
  • Simioni S, Cavassini M, Annoni JM, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS. 2010;24(9):1243–1250.
  • Anand P, Springer SA, Copenhaver MM, Altice FL. Neurocognitive impairment and HIV risk factors: a reciprocal relationship. AIDS Behav. 2010;14(6):1213–1226.
  • Bonnet F, Amieva H, Marquant F, et al; S CO3 Aquitaine Cohort. Cognitive disorders in HIV-infected patients: are they HIV-related? AIDS. 2013;27(3):391–400.
  • Anderson E, Zink W, Xiong H, Gendelman HE. HIV-1-associated dementia: a metabolic encephalopathy perpetrated by virus-infected and immune-competent mononuclear phagocytes. J Acquir Immune Defic Syndr. 2002;31(Suppl 2):S43–S54.
  • Nath A, Hauser KF, Wojna V, et al. Molecular basis for interactions of HIV and drugs of abuse. J Acquir Immune Defic Syndr. 2002;31(Suppl 2):S62–S69.
  • Churchill MJ, Wesselingh SL, Cowley D, et al. Extensive astrocyte infection is prominent in human immunodeficiency virus-associated dementia. Ann Neurol. 2009;66:253–258.
  • Hu NW, Ondrejcak T, Rowan MJ. Glutamate receptors in preclinical research on Alzheimer’s disease: update on recent advances. Pharmacol Biochem Behav. 2012;100(4):855–862.
  • Brack-Werner R, Kleinschmidt A, Ludvigsen A, et al. Infection of human brain cells by HIV-1: restricted virus production in chronically infected human glial cell lines. AIDS. 1992;6(3):273–285.
  • Tornatore C, Nath A, Amemiya K, Major EO. Persistent human immunodeficiency virus type 1 infection in human fetal glial cells reactivated by T-cell factor(s) or by the cytokines tumor necrosis factor alpha and interleukin-1 beta. J Virol. 1991;65(11):6094–6100.
  • Valcour V, Chalermchai T, Sailasuta N, et al; RV254/SEARCH 010 Study Group. Central nervous system viral invasion and inflammation during acute HIV infection. J Infect Dis. 2012;206:275–282.
  • Rao JS, Lee HJ, Rapoport SI, Bazinet RP. Mode of action of mood stabilizers: is the arachidonic acid cascade a common target? Mol Psychiatry. 2008;13(6):585–596.
  • Farooqui AA, Ong WY, Horrocks LA. Inhibitors of brain phospholipase A2 activity: their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders. Pharmacol Rev. 2006;58(3):591–620.
  • Müller N, Myint AM, Schwarz MJ. Inflammatory biomarkers and depression. Neurotox Res. 2011;19(2):308–318.
  • Bazinet RP. Is the brain arachidonic acid cascade a common target of drugs used to manage bipolar disorder? Biochem Soc Trans. 2009;37(Pt 5):1104–1109.
  • Leonard B, Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev. 2012;36(2):764–785.
  • Kim K, Lee SG, Kegelman TP, et al. Role of excitatory amino acid transporter-2 (EAAT2) and glutamate in neurodegeneration: opportunities for developing novel therapeutics. J Cell Physiol. 2011;226(10):2484–2493.
  • Müller N, Schwarz MJ. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol Psychiatry. 2007;12(11):988–1000.
  • de Pablos RM, Herrera AJ, Espinosa-Oliva AM, et al. Chronic stress enhances microglia activation and exacerbates death of nigral dopaminergic neurons under conditions of inflammation. J Neuroinflammation. 2014;11:34.
  • Vázquez-Santiago FJ, Noel RJ Jr, Porter JT, Rivera-Amill V. Glutamate metabolism and HIV-associated neurocognitive disorders. J Neurovirol. 2014;20(4):315–331.
  • Kousik SM, Napier TC, Carvey PM. The effects of psychostimulant drugs on blood brain barrier function and neuroinflammation. Front Pharmacol. 2012;3:121.
  • Sharma HS, Sjöquist PO, Ali SF. Drugs of abuse-induced hyperthermia, blood- brain barrier dysfunction and neurotoxicity: neuroprotective effects of a new antioxidant compound H-290/51. Curr Pharm Des. 2007;13(18):1903–1923.
  • Sharma HS, Muresanu D, Sharma A, Patnaik R. Cocaine-induced breakdown of the blood-brain barrier and neurotoxicity. Int Rev Neurobiol. 2009;88:297–334.
  • Silverstein PS, Shah A, Gupte R, et al. Methamphetamine toxicity and its implications during HIV-1 infection. J Neurovirol. 2011;17(5):401–415.
  • Flora G, Lee YW, Nath A, Maragos W, Hennig B, Toborek M. Methamphetamine-induced TNF-alpha gene expression and activation of AP-1 in discrete regions of mouse brain: potential role of reactive oxygen intermediates and lipid peroxidation. Neuromolecular Med. 2002;2(1):71–85.
  • Noel RJ Jr, Rivera-Amill V, Buch S, Kumar A. Opiates, immune system, acquired immunodeficiency syndrome, and nonhuman primate model. J Neurovirol. 2008;14(4):279–285.
  • Anthony IC, Ramage SN, Carnie FW, Simmonds P, Bell JE. Does drug abuse alter microglial phenotype and cell turnover in the context of advancing HIV infection? Neuropathol Appl Neurobiol. 2005;31(3):325–338.
  • Singhal PC, Sharma P, Kapasi AA, Reddy K, Franki N, Gibbons N. Morphine enhances macrophage apoptosis. J Immunol. 1998;160(4):1886–1893.
  • Wang X, Zhang T, Ho WZ. Opioids and HIV/HCV infection. J Neuroimmune Pharmacol. 2011;6(4):477–489.
  • El-Hage N, Wu G, Wang J, et al. HIV-1 Tat and opiate-induced changes in astrocytes promote chemotaxis of microglia through the expression of MCP-1 and alternative chemokines. Glia. 2006;53(2):132–146.
  • El-Hage N, Wu G, Ambati J, Bruce-Keller AJ, Knapp PE, Hauser KF. CCR2 mediates increases in glial activation caused by exposure to HIV-1 Tat and opiates. J Neuroimmunol. 2006;178(1–2):9–16.
  • Khurdayan VK, Buch S, El-Hage N, et al. Preferential vulnerability of astroglia and glial precursors to combined opioid and HIV-1 Tat exposure in vitro. Eur J Neurosci. 2004;19(12):3171–3182.
  • Chao CC, Gekker G, Hu S, Sheng WS, Portoghese PS, Peterson PK. Upregulation of HIV-1 expression in cocultures of chronically infected promonocytes and human brain cells by dynorphin. Biochem Pharmacol. 1995;50(5):715–722.
  • Chao CC, Gekker G, Hu S, et al. Kappa opioid receptors in human microglia downregulate human immunodeficiency virus 1 expression. Proc Natl Acad Sci U S A. 1996;93(15):8051–8056.
  • Chao CC, Hu S, Gekker G, Lokensgard JR, Heyes MP, Peterson PK. U50, 488 protection against HIV-1-related neurotoxicity: involvement of quinolinic acid suppression. Neuropharmacology. 2000;39(1):150–160.
  • Baldwin JA, Maxwell CJ, Fenaughty AM, Trotter RT, Stevens SJ. Alcohol as a risk factor for HIV transmission among American Indian and Alaska Native drug users. Am Indian Alsk Native Ment Health Res. 2000;9(1):1–16.
  • Tyor WR, Middaugh LD Do alcohol and cocaine abuse alter the course of HIV- associated dementia complex? J Leukoc Biol. 1999;65(4):475–481.
  • Rudolph JG, Lemasters JJ, Crews FT. Effects of chronic ethanol exposure on oxidation and NMDA-stimulated neuronal death in primary neuronal cultures. Alcohol Clin Exp Rex 1998;22(9):2080–2085.
  • Chandler LJ, Newsom H, Sumners C, Crews F. Chronic ethanol exposure potentiates NMDA excitotoxicity in cerebral cortical neurons. J Neurochem. 1993;60(4):1578–1581.
  • Sillaber I, Rammes G, Zimmermann S, et al. Enhanced and delayed stress-induced alcohol drinking in mice lacking functional CRH1 receptors. Science. 2002;296(5569):931–933.
  • Kaur S, Li J, Stenzel-Poore MP, Ryabinin AE. Corticotropin-releasing factor acting on corticotropin-releasing factor receptor type 1 is critical for binge alcohol drinking in mice. Alcohol Clin Exp Res. 2012;36(2):369–376.
  • Lowery EG, Spanos M, Navarro M, Lyons AM, Hodge CW, Thiele TE. CRF-1 antagonist and CRF-2 agonist decrease binge-like ethanol drinking in C57BL/6J mice independent of the HPA axis. Neuropsychopharmacology. 2010;35:1241–1252.
  • Sparta DR, Sparrow AM, Lowery EG, Fee JR, Knapp DJ, Thiele TE. Blockade of the corticotropin releasing factor type 1 receptor attenuates elevated ethanol drinking associated with drinking in the dark procedures. Alcohol Clin Exp Res. 2008;32:259–265.
  • Gehlert DR, Cippitelli A, Thorsell A, et al. 3-(4-Chloro-2-morpholin-4-yl-thiazol-5-yl)-8-(1-ethylpropyl)-2,6-dimethyl-imidazo[1,2-b]pyridazine: a novel brain-penetrant, orally available corticotropin-releasing factor receptor 1 antagonist with efficacy in animal models of alcoholism. J Neurosci. 2007;27:2718–2726.
  • Arango JC, Simmonds P, Brettle RP, Bell JE. Does drug abuse influence the microglial response in AIDS and HIV encephalitis? AIDS. 2004;18(Suppl 1):S69–S74.
  • Kreek MJ, LaForge KS Butelman E. Pharmacotherapy of addictions. Nat Rev Drug Discov. 2002;1:710–726.
  • Logrip ML, Koob GF, Zorrilla EP. Role of corticotropin-releasing factor in drug addiction: potential for pharmacological intervention. CNS Drugs. 2011;25(4):271–287.
  • Refojo D, Schweizer M, Kuehne C, et al. Glutamatergic and dopaminergic neurons mediate anxiogenic and anxiolytic effects of CRHR1. Science. 2011;333(6051):1903–1907.
  • Tung J, Barreiro LB, Johnson ZP, et al. Social environment is associated with gene regulatory variation in the rhesus macaque immune system. Proc Natl Acad Sci U S A. 2012;109(17):6490–6495.
  • Sapolsky RM. The influence of social hierarchy on primate health. Science. 2005;308:648–652.
  • Sapolsky RM. Social status and health in humans and other animals. Annu Rev Anthropol. 2004;33:393–418.
  • Habib KE, Weld KP, Rice KC, et al. Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates. Proc Natl Acad Sci U S A. 2000;97(11):6079–6084.
  • Antoni MH, Cruess S, Cruess DG, et al. Cognitive-behavioral stress management reduces distress and 24-hour urinary free cortisol output among symptomatic HIV- infected gay men. Ann Behav Med. 2000;22(1):29–37.
  • Ickovics JR, Hamburger ME, Vlahov D, et al; HIV Epidemiology Research Study Group. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. JAMA. 2001;285(11):1466–1474.
  • Ickovics JR, Milan S, Boland R, Schoenbaum E, Schuman P, Vlahov D; HIV Epidemiology Research Study (HERS) Group. Psychological resources protect health: 5-year survival and immune function among HIV-infected women from four US cities. AIDS. 2006;20(14):1851–1860.
  • Cruess DG, Kalichman SC, Amaral C, Swetzes C, Cherry C, Kalichman MO. Benefits of adherence to psychotropic medications on depressive symptoms and antiretroviral medication adherence among men and women living with HIV/AIDS. Ann Behav Med. 2012;43(2):189–197.
  • Cruess DG, Antoni MH, Kumar M, Schneiderman N. Reductions in salivary cortisol are associated with mood improvement during relaxation training among HIV- seropositive men. J Behav Med. 2000;23(2):107–122.
  • Antoni MH. Stress management effects on psychological, endocrinological, and immune functioning in men with HIV infection: empirical support for a psychoneuroimmunological model. Stress. 2003;6(3):173–188.
  • Leserman J, Petitto JM, Golden RN, et al. Impact of stressful life events, depression, social support, coping, and cortisol on progression to AIDS. Am J Psychiatry. 2000;157(8):1221–1228.
  • Clerici M, Galli M, Bosis S, Gervasoni C, Moroni M, Norbiato G. Immunoendocrinologic abnormalities in human immunodeficiency virus infection. Ann N Y Acad Sci. 2000;917:956–961.
  • Schiepers OJ, Wichers MC, Maes M. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(2):201–217.
  • Müller N, Ackenheil M. Psychoneuroimmunology and the cytokine action in the CNS: implications for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry. 1998;22(1):1–33.
  • Bruce TO. Comorbid depression in rheumatoid arthritis: pathophysiology and clinical implications. Curr Psychiatry Rep. 2008;10(3):258–264.
  • Siegert RJ, Abernethy DA. Depression in multiple sclerosis: a review. J Neurol Neurosurg Psychiatry. 2005;76(4):469–475.
  • Valentine AD, Meyers CA, Kling MA, Richelson E, Hauser P. Mood and cognitive side effects of interferon-alpha therapy. Semin Oncol. 1998;25(1 Suppl 1):39–47.
  • Bonaccorso S, Puzella A, Marino V, et al. Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Res. 2001;105(1–2):45–55.
  • Meyers CA. Mood and cognitive disorders in cancer patients receiving cytokine therapy. In: Dantzer R, Wollman EE, Yirmiya R, editors. Cytokines, Stress, and Depression. New York: Kluwer Academic/Plenum Publishers; 1999:75–81.
  • Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009;65(9):732–741.
  • Walker Harris V, Brown TT. Bone loss in the HIV-infected patient: evidence, clinical implications, and treatment strategies. J Infect Dis. 2012;205(Suppl 3):S391–S398.
  • Giannarelli C, Klein RS, Badimon JJ. Cardiovascular implications of HIV- induced dyslipidemia. Atherosclerosis. 2011;219(2):384–389.
  • McComsey GA, Tebas P, Shane E, et al. Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis. 2010;51(8):937–946.
  • Chiba S, Numakawa T, Ninomiya M, Richards MC, Wakabayashi C, Kunugi H. Chronic restraint stress causes anxiety- and depression-like behaviors, downregulates glucocorticoid receptor expression, and attenuates glutamate release induced by brain- derived neurotrophic factor in the prefrontal cortex. Prog Neuropsychopharmacol Biol Psychiatry. 2012;39(1):112–119.
  • Wise RA, Morales M. A ventral tegmental CRF-glutamate-dopamine interaction in addiction. Brain Res. 2010;1314:38–43.
  • Borgland SL, Ungless MA, Bonci A. Convergent actions of orexin/hypocretin and CRF on dopamine neurons: emerging players in addiction. Brain Res. 2010;1314:139–144.
  • Lowry CA, Moore FL. Regulation of behavioral responses by corticotropin- releasing factor. Gen Comp Endocrinol. 2006;146(1):19–27.
  • Pace TW, Miller AH. Cytokines and glucocorticoid receptor signaling. Relevance to major depression. Ann N Y Acad Sci. 2009;1179:86–105.
  • Butts CL, Jones YL, Lim JK, Salter CE, Belyavskaya E, Sternberg EM. Tissue expression of steroid hormone receptors is associated with differential immune responsiveness. Brain Behav Immun. 2011;25(5):1000–1007.
  • Muthumani K, Choo AY, Zong WX, et al. The HIV-1 Vpr and glucocorticoid receptor complex is a gain-of-function interaction that prevents the nuclear localization of PARP-1. Nat Cell Biol. 2006;8(2):170–179.
  • Kino T, Gragerov A, Kopp JB, Stauber RH, Pavlakis GN, Chrousos GP. The HIV-1 virion-associated protein vpr is a coactivator of the human glucocorticoid receptor. J Exp Med. 1999;189(1):51–62.
  • Kinter AL, Biswas P, Alfano M, et al. Interleukin-6 and glucocorticoids synergistically induce human immunodeficiency virus type-1 expression in chronically infected U1 cells by a long terminal repeat independent post-transcriptional mechanism. Mol Med. 2001;7(10):668–678.
  • Corley PA. Interleukin-1 receptor antagonist as a treatment of HIV infection. Med Hypotheses. 2000;54(4):513–518.
  • Llorens-Martín M, Trejo JL. Mifepristone prevents stress-induced apoptosis in newborn neurons and increases AMPA receptor expression in the dentate gyrus of C57/BL6 mice. PLoS One. 2011;6(11):e28376.
  • Donia M, Anzaldi M, Di Marco R, et al. Phase II study of the antiretroviral activity and safety of the glucocorticoid receptor antagonist mifepristone in HIV-1- infected patients. Int J Mol Med. 2011;28(3):437–442.
  • Campos LN, Guimarães MD, Remien RH. Anxiety and depression symptoms as risk factors for non-adherence to antiretroviral therapy in Brazil. AIDS Behav. 2010;14(2):289–299.
  • DeLorenze GN, Satre DD, Quesenberry CP, Tsai AL, Weisner CM. Mortality after diagnosis of psychiatric disorders and co-occurring substance use disorders among HIV-infected patients. AIDS Patient Care STDS. 2010;24(11):705–712.
  • Handwerger K. Differential patterns of HPA activity and reactivity in adult posttraumatic stress disorder and major depressive disorder. Harv Rev Psychiatry. 2009;17(3):184–205.
  • Mackesy-Amiti ME, Donenberg GR, Ouellet LJ. Prevalence of psychiatric disorders among young injection drug users. Drug Alcohol Depend. 2012;124(1–2):70–78.
  • Logie CH, Newman PA, Chakrapani V, Shunmugam M. Adapting the minority stress model: associations between gender non-conformity stigma, HIV-related stigma and depression among men who have sex with men in South India. Soc Sci Med. 2012;74(8):1261–1268.
  • Dyer TP, Shoptaw S, Guadamuz TE, et al. Application of syndemic theory to black men who have sex with men in the Multicenter AIDS Cohort Study. J Urban Health. 2012;89(4):697–708.
  • Mayne TJ, Vittinghoff E, Chesney MA, Barrett DC, Coates TJ. Depressive affect and survival among gay and bisexual men infected with HIV. Arch Intern Med. 1996;156(19):2233–2238.
  • Burack JH, Barrett DC, Stall RD, Chesney MA, Ekstrand ML, Coates TJ. Depressive symptoms and CD4 lymphocyte decline among HIV-infected men. JAMA. 1993:270(21):2568–2573.
  • Anderson RN, Smith BL. Deaths: leading causes for 2001. Natl Vital Stat Rep. 2003;52:1–85.
  • Risk by Gender [webpage on the Internet]. Atlanta: Centers for Disease Control and Prevention (CDC) [updated June 29, 2015]. Available from: http://www.cdc.gov/hiv/group/gender/index.html. Accessed July 20, 2015.
  • Orlando M, Burnam MA, Beckman R, et al. Re-estimating the prevalence of psychiatric disorders in a nationally representative sample of persons receiving care for HIV: results from the HIV Cost and Services Utilization Study. Int J Methods Psychiatr Res. 2002;11(2):75–82.
  • Cook JA, Grey D, Burke-Miller J, et al. Effects of treated and untreated depressive symptoms on highly active antiretroviral therapy use in a US multi-site cohort of HIV-positive women. AIDS Care. 2006;18(2):93–100.
  • Cook JA, Grey DD, Burke-Miller JK, et al. Illicit drug use, depression and their association with highly active antiretroviral therapy in HIV-positive women. Drug Alcohol Depend. 2007;89(1):74–81.
  • Kumar V, Encinosa W. Effects of antidepressant treatment on antiretroviral regimen adherence among depressed HIV-infected patients. Psychiatr Q. 2009;80(3):131–141.
  • Cole SW. Psychosocial influences on HIV-1 disease progression: neural, endocrine, and virologic mechanisms. Psychosom Med. 2008;70(5):562–568.
  • Creswell JD, Myers HF, Cole SW, Irwin MR. Mindfulness meditation training effects on CD4+ T lymphocytes in HIV-1 infected adults: a small randomized controlled trial. Brain Behav Immun. 2009;23(2):184–188.
  • Ironson G, O’Cleirigh C, Fletcher MA, et al. Psychosocial factors predict CD4 and viral load change in men and women with human immunodeficiency virus in the era of highly active antiretroviral treatment. Psychosom Med. 2005;67(6):1013–1021.
  • Leserman J, Petitto JM, Gu H, et al. Progression to AIDS, a clinical AIDS condition and mortality: psychosocial and physiological predictors. Psychol Med. 2002;32(6):1059–1073.
  • Carrico AW, Antoni MH. Effects of psychological interventions on neuroendocrine hormone regulation and immune status in HIV-positive persons: a review of randomized controlled trials. Psychosom Med. 2008;70(5):575–584.
  • Merali Z, Du L, Hrdina P, et al. Dysregulation in the suicide brain: mRNA expression of corticotropin-releasing hormone receptors and GABA(A) receptor subunits in frontal cortical brain region. J Neurosci. 2004;24(6):1478–1485.
  • Iyer AM, Brooke SM, Sapolsky RM. Glucocorticoids interact with gp120 in causing neurotoxicity in striatal cultures. Brain Res. 1998;808(2):305–309.
  • Lee AL, Ogle WO, Sapolsky RM. Stress and depression: possible links to neuron death in the hippocampus. Bipolar Disord. 2002;4(2):117–128.
  • Brogan J, Li F, Li W, He Z, Huang Q, Li CY. Imaging molecular pathways: reporter genes. Radiat Res. 2012;177(4):508–513.
  • Smith TA. Towards detecting the HER-2 receptor and metabolic changes induced by HER-2-targeted therapies using medical imaging. Br J Radiol. 2010;83(992):638–644.
  • Zhang Y, Hong H, Cai W. PET tracers based on Zirconium-89. Curr Radiopharm. 2011;4(2):131–139.
  • de Pablos RM, Villarán RF, Argüelles S, et al. Stress increases vulnerability to inflammation in the rat prefrontal cortex. J Neurosci. 2006;26(21):5709–5719.
  • Frank MG, Thompson BM, Watkins LR, Maier SF. Glucocorticoids mediate stress-induced priming of microglial pro-inflammatory responses. Brain Behav Immun. 2012;26(2):337–345.
  • Watson S, Gallagher P, Porter RJ, Smith MS, Herron LJ, Bulmer S; North-East Mood Disorders Clinical Research Group, Young AH, Ferrier IN. A randomized trial to examine the effect of mifepristone on neuropsychological performance and mood in patients with bipolar depression. Biol Psychiatry. 2012;72(11):943–949.
  • DeBattista C, Belanoff J, Glass S, et al. Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression. Biol Psychiatry. 2006;60(12):1343–1349.
  • Gallagher P, Young AH. Mifepristone (RU-486) treatment for depression and psychosis: a review of the therapeutic implications. Neuropsychiatr Dis Treat. 2006;2(1):33–42.
  • Belanoff JK, Rothschild AJ, Cassidy F, et al. An open label trial of C-1073 (mifepristone) for psychotic major depression. Biol Psychiatry. 2002;52(5):386–392.
  • Kiferle L, Politis M, Muraro PA, Piccini P. Positron emission tomography imaging in multiple sclerosis-current status and future applications. Eur J Neurol. 2011;18(2):226–231.
  • Ratchford JN, Endres CJ, Hammoud DA, et al. Decreased microglial activation in MS patients treated with glatiramer acetate. J Neurol. 2012;259(6):1199–1205.
  • Venneti S, Lopresti BJ, Wang G, et al. PET imaging of brain macrophages using the peripheral benzodiazepine receptor in a macaque model of neuroAIDS. J Clin Invest. 2004;113(7):981–989.
  • Wiley CA, Lopresti BJ, Becker JT, et al. Positron emission tomography imaging of peripheral benzodiazepine receptor binding in human immunodeficiency virus-infected subjects with and without cognitive impairment. J Neurovirol. 2006;12(4):262–271.
  • Hammoud DA, Endres CJ, Chander AR, et al. Imaging glial cell activation with [11C]-R-PK11195 in patients with AIDS. J Neurovirol. 2005;11(4):346–355.
  • Adinoff B, Anton R, Linnoila M, Guidotti A, Nemeroff CB, Bissette G. Cerebrospinal fluid concentrations of corticotropin-releasing hormone (CRH) and diazepam-binding inhibitor (DBI) during alcohol withdrawal and abstinence. Neuropsychopharmacology. 1996;15(3):288–295.
  • Arató M, Bánki CM, Bissette G, Nemeroff CB. Elevated CSF CRF in suicide victims. Biol Psychiatry. 1989;25(3):355–359.
  • Nemeroff CB, Owens MJ, Bissette G, Andorn AC, Stanley M. Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Arch Gen Psychiatry. 1988;45(6):577–579.
  • Banki CM, Bissette G, Arato M, O’Connor L, Nemeroff CB. CSF corticotropin- releasing factor-like immunoreactivity in depression and schizophrenia. Am J Psychiatry. 1987;144(7):873–877.
  • Koob GF, Zorrilla EP. Update on corticotropin-releasing factor pharmacotherapy for psychiatric disorders: a revisionist view. Neuropsychopharmacology. 2012;37(1):308–309.
  • Zorrilla EP, Koob GF. Progress in corticotropin-releasing factor-1 antagonist development. Drug Discov Today. 2010;15(9–10):371–383.
  • Zobel AW, Nickel T, Künzel HE, et al. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res. 2000;34(3):171–181.
  • Fleck BA, Hoare SR, Pick RR, Bradbury MJ, Grigoriadis DE. Binding kinetics redefine the antagonist pharmacology of the corticotropin-releasing factor type 1 receptor. J Pharmacol Exp Ther. 2012;341(2):518–531.
  • Ramsey SJ, Attkins NJ, Fish R, van der Graaf PH. Quantitative pharmacological analysis of antagonist binding kinetics at CRF1 receptors in vitro and in vivo. Br J Pharmacol. 2011;164(3):992–1007.
  • Bornstein SR, Webster EL, Torpy DJ, et al. Chronic effects of a nonpeptide corticotropin-releasing hormone type I receptor antagonist on pituitary-adrenal function, body weight, and metabolic regulation. Endocrinology. 1998;139(4):1546–1555.
  • Martinez V, Taché Y. CRF1 receptors as a therapeutic target for irritable bowel syndrome. Curr Pharm Des. 2006;12(31):4071–4088.
  • Hubbard CS, Labus JS, Bueller J, et al. Corticotropin-releasing factor receptor 1 antagonist alters regional activation and effective connectivity in an emotional-arousal circuit during expectation of abdominal pain. J Neurosci. 2011;31(35):12491–12500.
  • Moskowitz JT. Positive affect predicts lower risk of AIDS mortality. Psychosom Med. 2003;65(4):620–626.
  • Benton TD. Depression and HIV/AIDS. Curr Psychiatry Rep. 2008;10:280–285.
  • Woods SP, Rippeth JD, Frol AB, et al. Interrater reliability of clinical ratings and neurocognitive diagnoses in HIV. J Clin Exp Neuropsychol. 2004;26(6):759–778.
  • Heaton RK, Kirson D, Velin RA, Grant I, The HNRC Group. The utility of clinical ratings for detecting cognitive change in HIV infection. In: Grant I, Martin A, editors. Neuropsychology of HIV Infection. New York: Oxford University Press; 1994:188–205.
  • Heaton RK, Taylor MJ, Manly JJ. Demographic effects and use of demographically corrected norms with the WAIS-III and WMS-III. In: Tulsky DS, Saklofske DH, Chelune GJ, et al, editors. Clinical Interpretation of the WAIS-III and WMS-III. San Diego: Academic Press; 2003:183–209.
  • Heaton RK, Miller SW, Taylor MJ, Grant I. Revised comprehensive norms for an expanded halstead-reitan battery: demographically adjusted neuropsychological norms for african american and caucasian adults, professional manual. Lutz: Psychological Assessment Resources; 2004. Available from: http://www4.parinc.com/Products/Product.aspx?ProductID=RCNAAC/ Accessed November 24, 2016.
  • Evans DL, Charney DS, Lewis L, et al. Mood disorders in the medically ill: scientific review and recommendations. Biol Psychiatry. 2005;58(3):175–189.
  • Kissane DW, Clarke DM, Street AF. Demoralization syndrome – a relevant psychiatric diagnosis for palliative care. J Palliat Care. 2001;17:12–21.
  • Dunn AJ, Swiergiel AH, de Beaurepaire R. Cytokines as mediators of depression: what can we learn from animal studies? Neurosci Biobehav Rev. 2005;29(4–5):891–909.
  • O’Brien SM, Scott LV, Dinan TG. Cytokines: abnormalities in major depression and implications for pharmacological treatment. Hum Psychopharmacol. 2004;19(6):397–403.
  • Matsuoka Y, Furuyashiki T, Yamada K, et al. Prostaglandin E receptor EP1 controls impulsive behavior under stress. Proc Natl Acad Sci U S A. 2005;102(44):16066–16071.
  • Lacosta S, Merali Z, Anisman H. Central monoamine activity following acute and repeated systemic interleukin-2 administration. Neuroimmunomodulation. 2000;8(2):83–90.
  • Murray M, Hogg RS, Lima VD, et al; Antiretroviral Therapy Cohort Collaboration (ART-CC). The effect of injecting drug use history on disease progression and death among HIV-positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis. HIV Med. 2012;13(2):89–97.
  • Cohn SE, Jiang H, McCutchan JA, et al. Association of ongoing drug and alcohol use with non-adherence to antiretroviral therapy and higher risk of AIDS and death: results from ACTG 362. AIDS Care. 2011;23(6):775–785.
  • Obel N, Omland LH, Kronborg G, et al. Impact of non-HIV and HIV risk factors on survival in HIV-infected patients on HAART: a population-based nationwide cohort study. PLoS One. 2011;6(7):e22698.
  • Rodríguez-Arenas MA, Jarrín I, del Amo J, et al; CoRIS-MD. Delay in the initiation of HAART, poorer virological response, and higher mortality among HIV-infected injecting drug users in Spain. AIDS Res Hum Retroviruses. 2006;22(8):715–723.
  • Nava F, Caldiroli E, Premi S, Lucchini A. Relationship between plasma cortisol levels, withdrawal symptoms and craving in abstinent and treated heroin addicts. J Addict Dis. 2006;25(2):9–16.
  • Dave RS, Khalili K. Morphine treatment of human monocyte-derived macrophages induces differential miRNA and protein expression: impact on inflammation and oxidative stress in the central nervous system. J Cell Biochem. 2010;110(4):834–845.
  • Hauser KF, El-Hage N, Stiene-Martin A, et al. HIV-1 neuropathogenesis: glial mechanisms revealed through substance abuse. J Neurochem. 2007;100(3):567–586.
  • Hauser KF, El-Hage N, Buch S, et al. Impact of opiate-HIV-1 interactions on neurotoxic signaling. J Neuroimmune Pharmacol. 2006;1(1):98–105.
  • Hauser KF, El-Hage N, Buch S, et al. Molecular targets of opiate drug abuse in neuroAIDS. Neurotox Res. 2005;8(1–2):63–80.
  • Hauser KF, Fitting S, Dever SM, Podhaizer EM, Knapp PE. Opiate drug use and the pathophysiology of neuroAIDS. Curr HIV Res. 2012;10(5):435–452.
  • Najt P, Fusar-Poli P, Brambilla P. Co-occurring mental and substance abuse disorders: a review on the potential predictors and clinical outcomes. Psychiatry Res. 2011;186(2–3):159–164.
  • Kelly TM, Daley DC, Douaihy AB. Treatment of substance abusing patients with comorbid psychiatric disorders. Addict Behav. 2012;37(1):11–24.
  • Gould RW, Porrino LJ, Nader MA. Nonhuman Primate Models of Addiction and PET Imaging: Dopamine System Dysregulation. In: Carter CS, Dalley JW, editors. Brain Imaging in Behavioral Neuroscience. Springer-Verlag Berlin Heidelberg. 2011;25–44.
  • Yau JL, Noble J, Thomas S, et al. The antidepressant desipramine requires the ABCB1 (Mdr1)-type p-glycoprotein to upregulate the glucocorticoid receptor in mice. Neuropsychopharmacology. 2007;32(12):2520–2529.
  • Pariante CM, Makoff A, Lovestone S, et al. Antidepressants enhance glucocorticoid receptor function in vitro by modulating the membrane steroid transporters. Br J Pharmacol. 2001;134(6):1335–1343.
  • Pariante CM, Kim RB, Makoff A, Kerwin RW. Antidepressant fluoxetine enhances glucocorticoid receptor function in vitro by modulating membrane steroid transporters. Br J Pharmacol. 2003;139(6):1111–1118.
  • Kenis G, Maes M. Effects of antidepressants on the production of cytokines. Int J Neuropsychopharmacol. 2002;5(4):401–412.
  • Eller T, Vasar V, Shlik J, Maron E. Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(2):445–450.
  • Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology. 2000;22(4):370–379.
  • Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology. 2000;22(4):370–379.
  • Castanon N, Leonard BE, Neveu PJ, Yirmiya R. Effects of antidepressants on cytokine production and actions. Brain Behav Immun. 2002;16(5):569–574.
  • Leonard BE. The immune system, depression and the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry. 2001;25(4):767–780.
  • Goebel M, Stengel A, Wang L, Reeve J Jr, Taché Y. Lipopolysaccharide increases plasma levels of corticotropin-releasing hormone in rats. Neuroendocrinology. 2011;93(3):165–173.
  • Buckinx R, Adriaensen D, Nassauw LV, Timmermans JP Corticotrophin-releasing factor, related peptides, and receptors in the normal and inflamed gastrointestinal tract. Front Neurosci. 2011;5:54.
  • Wallon C, Söderholm JD. Corticotropin-releasing hormone and mast cells in the regulation of mucosal barrier function in the human colon. Ann N Y Acad Sci. 2009;1165:206–210.
  • Fukudo S. Role of corticotropin-releasing hormone in irritable bowel syndrome and intestinal inflammation. J Gastroenterol. 2007;42(Suppl 17):48–51.
  • Iyer AM, Brooke SM, Sapolsky RM. Glucocorticoids interact with gp120 in causing neurotoxicity in striatal cultures. Brain Res. 1998;808(2):305–309.
  • Kling MA, Coleman VH, Schulkin J. Glucocorticoid inhibition in the treatment of depression: can we think outside the endocrine hypothalamus? Depress Anxiety. 2009;26(7):641–649.
  • McEwen BS. Plasticity of the hippocampus: adaptation to chronic stress and allostatic load. Ann N Y Acad Sci. 2001;933:265–277.
  • Bremner JD. Stress and brain atrophy. CNS Neurol Disord Drug Targets. 2006;5(5):503–512.

References

  • Brabers NA, Nottet HS. Role of the pro-inflammatory cytokines TNF-alpha and IL-1beta in HIV-associated dementia. Eur J Clin Invest. 2006;36(7):447–458.
  • Cysique LA, Vaida F, Letendre S, et al. Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology. 2009;73(5):342–348.
  • Croteau D. Psychology and AIDS Exchange Newsletter. January 2013.
  • de Pablos RM, Herrera AJ, Espinosa-Oliva AM, et al. Chronic stress enhances microglia activation and exacerbates death of nigral dopaminergic neurons under conditions of inflammation. J Neuroinflammation. 2014;11:34.
  • Erdmann N, Tian C, Huang Y>, et al. In vitro glutaminase regulation and mechanisms of glutamate generation in HIV-1-infected macrophage. J Neurochem. 2009;109(2):551–561.
  • Erdmann NB, Whitney NP, Zheng J. Potentiation of excitotoxicity in HIV-1 associated dementia and the significance of glutaminase. Clin Neurosci Res. 2006;6(5):315–328.
  • Frank MG, Hershman SA, Weber MD, Watkins LR, Maier SF. Chronic exposure to exogenous glucocorticoids primes microglia to pro-inflammatory stimuli and induces NLRP3 mRNA in the hippocampus. Psychoneuroendocrinology. 2014;40:191–200.
  • Frank MG, Thompson BM, Watkins LR, Maier SF. Glucocorticoids mediate stress-induced priming of microglial pro-inflammatory responses. Brain Behav Immun. 2012;26(2):337–345.
  • Gold SM, Sasidhar MV, Lagishetty V, et al. Dynamic development of glucocorticoid resistance during autoimmune neuroinflammation. J Clin Endocrinol Metab. 2012;97(8):E1402–E1410.
  • Sugama S, Takenouchi T, Fujita M, Kitani H, Conti B, Hashimoto M. Corticosteroids limit microglial activation occurring during acute stress. Neuroscience. 2013;232:13–20.
  • Tian C, Erdmann N, Zhao J, Cao Z, Peng H, Zheng J. HIV-infected macrophages mediate neuronal apoptosis through mitochondrial glutaminase. J Neurochem. 2008;105(3):994–1005.
  • Vázquez-Santiago FJ, Noel RJ Jr, Porter JT, Rivera-Amill V. Glutamate metabolism and HIV-associated neurocognitive disorders. J Neurovirol. 2014;20(4):315–331.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.